The clinical utility of the proliferating cell nuclear antigen expression in patients with hepatocellular carcinoma
Proliferating cell nuclear antigen (PCNA) has been suggested as a potential diagnostic biomarker for early hepatocellular carcinoma (HCC). However, its prognostic significance in HCC remains unclear. In the present study, we investigated the expression and significance of PCNA in HCC and then analyzed the role of PCNA in clinical outcomes. Our findings show that the expression intensity of PCNA is much higher in HCC tissues than that in paracarcinoma tissues and associated with AFP, albumin, tumor number, clinical grade, vascular invasion, and tumor-node-metastasis (TNM) stage (all p < 0.000). Kaplan-Meier analysis indicated that high PCNA expression was associated with poor disease-free survival (DFS) (p < 0.000) and overall survival (OS) (p < 0.000) in a training cohort of 76 HCC patients. Multiple Cox regression analysis indicated PCNA acts as an independent predictor for DFS (p = 0.002) and OS (p = 0.004) in HCC patients. Along with pathological results, our systematic review also identified the expression of PCNA was closely associated with DFS and OS (both p < 0.000). In conclusion, this study suggested that PCNA is increased in HCC patients and is indeed a novel unfavorable biomarker for prognostic prediction for patients with this deadly disease.
KeywordsPCNA HCC Clinical utility
We greatly thank other members of our lab for valuable suggestions and writing.
Compliance with ethical standards
This study was approved by the Ethics Committee of Shandong Cancer Hospital and Institute and complied with the Declaration of Helsinki. All of the patients provided written informed consent.
- 10.Pan Y, Zhang Y, Chen L, Liu Y, Feng Y, Yan J. The critical role of Rab31 in cell proliferation and apoptosis in cancer progression. Mol Neurobiol. 2015. [Epub ahead of print] PMID: 26245486Google Scholar
- 12.Cao J, Hu X, Xie M, Sun J, Cheng H. Expression of proliferating cell nuclear antigen and alpha-fetoprotein in hepatocellular carcinoma and its clinical significance. Pract J Cancer. 1998;13(2):105–7.Google Scholar
- 13.Zhang Z, Wu Q, Hua Z, Zhou Z, Jia Z, Wang H. The expression of PCNA CD44v6 in human hepatic carcinoma and its clinical significance. Hainan Med J. 2000;11(6):8–11.Google Scholar
- 16.Zhao Z, Zhan Y, Ni Y, Zhang M, Wang C. Prognosis and the expression of survivin protein and proliferating cell nuclear antigen (PCNA) in hepatocellular carcinoma. Shenzhen J Int Trad Chin West Med. 2007;17(6):355–7.Google Scholar
- 17.Hu TH, Wang CC, Huang CC, Chen CL, Hung CH, Chen CH, et al. Down-regulation of tumor suppressor gene PTEN, overexpression of p53, plus high proliferating cell nuclear antigen index predict poor patient outcome of hepatocellular carcinoma after resection. Oncol Rep. 2007;18(6):1417–26.PubMedGoogle Scholar
- 18.Gao F, Yang J, Liu B, Ma F, Geng Y, Li J. Expressions of PCNA and Hpa and their correlations with prognosis of patients with hepatocellular carcinoma. Hebei Med J. 2013;35(16):2410–2.Google Scholar
- 22.Lan HA, Zain RB, Saitoh M, Muramatsu Y, Shrestha P, Mori M. Proliferating cell nuclear antigen and p53 in epithelial dysplasia and squamous cell carcinoma of oral mucosa—a marker for poor tumour differentiation, increasing nuclear atypia and invasiveness. Anticancer Res. 1996;16:3059–65.PubMedGoogle Scholar
- 23.Lv Q, Zhang J, Yi Y, Huang Y, Wang Y, Wang Y, et al. Proliferating cell nuclear antigen has an association with prognosis and risks factors of cancer patients: a systematic review. Mol Neurobiol. 2015. [Epub ahead of print] PMID: 26558632Google Scholar
- 24.Li J, Li H, Liu J, Feng B, Feng M, Lv B, et al. The clinical implications of human telomerase reverse transcriptase expression in grade and prognosis of gliomas: a systematic review and meta-analysis. Mol Neurobiol. 2015. [Epub ahead of print].Google Scholar